{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:24:20Z","timestamp":1767374660729},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2003,2,1]],"date-time":"2003-02-01T00:00:00Z","timestamp":1044057600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2003,2]]},"DOI":"10.1007\/s11912-003-0084-9","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T14:46:25Z","timestamp":1180709185000},"page":"29-40","source":"Crossref","is-referenced-by-count":30,"title":["Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis"],"prefix":"10.1007","volume":"5","author":[{"given":"Stacey L.","family":"Berg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc C.","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"84_CR1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/1097-0142(197008)26:2<404::AID-CNCR2820260222>3.0.CO;2-I","volume":"26","author":"A Evans","year":"1970","unstructured":"Evans A, Gilbert E, Zandstra R: The increasing incidence of central nervous system leukemia in children. Cancer 1970, 26:404\u2013407.","journal-title":"Cancer"},{"key":"84_CR2","first-page":"579","volume":"19","author":"J Posner","year":"1978","unstructured":"Posner J, Chernik N: Intracranial metastases from systemic cancer. Adv Neurol 1978, 19:579\u2013592.","journal-title":"Adv Neurol"},{"key":"84_CR3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/pgmj.56.653.149","volume":"56","author":"R Boyle","year":"1980","unstructured":"Boyle R, Thomas M, Adams J: Diffuse involvement of the leptomeninges by tumour: a clinical and pathological study of 63 cases. Postgrad Med J 1980, 56:149\u2013158.","journal-title":"Postgrad Med J"},{"key":"84_CR4","first-page":"461","volume":"25","author":"S Bigner","year":"1981","unstructured":"Bigner S, Johnston W: The cytopathology of cerebrospinal fluid. Acta Cytol 1981, 25:461\u2013477.","journal-title":"Acta Cytol"},{"key":"84_CR5","first-page":"164","volume":"6","author":"HT Whelan","year":"1987","unstructured":"Whelan HT, Sung JH, Mastri AR: Diffuse leptomeningeal gliomatosis: report of three cases. Clin Neuropathol 1987, 6:164\u2013168.","journal-title":"Clin Neuropathol"},{"key":"84_CR6","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1212\/WNL.38.4.562","volume":"38","author":"LA Civitello","year":"1988","unstructured":"Civitello LA, Packer RJ, Rorke LB, et al.: Leptomeningeal dissemination of low-grade gliomas in childhood. Neurology 1988, 38:562\u2013566.","journal-title":"Neurology"},{"key":"84_CR7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF01050262","volume":"15","author":"G Davila","year":"1993","unstructured":"Davila G, Duyckaerts C, Lazareth JP, et al.: Diffuse primary leptomeningeal gliomatosis. J Neuro Oncol 1993, 15:45\u201349.","journal-title":"J Neuro Oncol"},{"key":"84_CR8","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1017\/S031716710004717X","volume":"12","author":"P Bailey","year":"1985","unstructured":"Bailey P, Robitaille Y: Primary diffuse leptomeningeal gliomatosis. Can J Neurol Sci 1985, 12:278\u2013281.","journal-title":"Can J Neurol Sci"},{"key":"84_CR9","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/0090-3019(84)90305-7","volume":"22","author":"J Ausman","year":"1984","unstructured":"Ausman J, Shrontz C, Chason J, et al.: Aggressive choroid plexus papilloma. Surg Neurol 1984, 22:472\u2013476.","journal-title":"Surg Neurol"},{"key":"84_CR10","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/0360-3016(84)90170-6","volume":"10","author":"M Deutsch","year":"1984","unstructured":"Deutsch M: The impact of myelography on the treatment results for medulloblastoma. Int J Rad Oncol Biol Phys 1984, 10:999\u20131003.","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"84_CR11","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/088307389300800403","volume":"8","author":"MT Jennings","year":"1993","unstructured":"Jennings MT, Slatkin N, D\u2019Angelo M, et al.: Neoplastic meningitis as the presentation of occult primitive neuroectodermal tumors. J Child Neurol 1993, 8:306\u2013312.","journal-title":"J Child Neurol"},{"key":"84_CR12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3171\/jns.1989.70.1.0031","volume":"70","author":"GW Ross","year":"1989","unstructured":"Ross GW, Rubenstein LJ: Lack of histopathological correlation of malignant ependymomas with postoperative survival. J Neurosurg 1989, 70:31\u201336.","journal-title":"J Neurosurg"},{"key":"84_CR13","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/0360-3016(85)90300-1","volume":"11","author":"M Trigg","year":"1985","unstructured":"Trigg M, Makuch R, Glaubiger D: Actuarial risk of isolated CNS involvement in Ewing\u2019s sarcoma following prophylactic cranial irradiation and methotrexate. Int J Radiat Oncol Biol Phys 1985, 11:699\u2013702.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"84_CR14","doi-asserted-by":"crossref","unstructured":"Jenkin R, Simpson W, Keen C: Pineal and suprasellar germinomas: Results of treatment. J Neurosurg 1978, 99\u2013107.","DOI":"10.3171\/jns.1978.48.1.0099"},{"key":"84_CR15","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1002\/1097-0142(19910601)67:11<2766::AID-CNCR2820671109>3.0.CO;2-#","volume":"67","author":"J Goldwein","year":"1991","unstructured":"Goldwein J, Corn B, Findlay J, et al.: Is craniospinal irradiation required to cure children with malignant (anaplastic) intracranial ependymomas? Cancer 1991, 67:2766\u20132771.","journal-title":"Cancer"},{"key":"84_CR16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1001\/archneur.1974.00490320010002","volume":"30","author":"M Olson","year":"1974","unstructured":"Olson M, Chernik N, Posner J: Infiltration of the leptomeninges by systemic cancer: a clinical and pathologic study. Arch Neurol 1974, 30:122\u2013137.","journal-title":"Arch Neurol"},{"key":"84_CR17","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/1097-0142(19820215)49:4<759::AID-CNCR2820490427>3.0.CO;2-7","volume":"49","author":"W Wasserstrom","year":"1982","unstructured":"Wasserstrom W, Glass J, Posner J: Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982, 49:759\u2013772.","journal-title":"Cancer"},{"key":"84_CR18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/archneur.1974.00490320026003","volume":"30","author":"J Little","year":"1974","unstructured":"Little J, Dale A, Okazaki H: Meningeal carcinomatosis: clinical manifestations. Arch Neurol 1974, 30:138\u2013143.","journal-title":"Arch Neurol"},{"key":"84_CR19","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/archneur.1981.00510110056008","volume":"38","author":"WH Theodore","year":"1981","unstructured":"Theodore WH, Gendelman S: Meningeal carcinomatosis. Arch Neurol 1981, 38:696\u2013699.","journal-title":"Arch Neurol"},{"key":"84_CR20","first-page":"25","volume":"92","author":"J Kaplan","year":"1990","unstructured":"Kaplan J, DeSouza T, Farkash A, et al.: Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 1990, 92:25\u201329.","journal-title":"J Neurooncol"},{"key":"84_CR21","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/1097-0142(19830101)51:1<154::AID-CNCR2820510130>3.0.CO;2-K","volume":"51","author":"C Kokkoris","year":"1983","unstructured":"Kokkoris C: Leptomeningeal carcinomatosis: how does cancer reach the pia-arachnoid? Cancer 1983, 51:154\u2013160.","journal-title":"Cancer"},{"key":"84_CR22","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1002\/1097-0142(197606)37:6<2906::AID-CNCR2820370648>3.0.CO;2-D","volume":"37","author":"J Gonzalez-Vitale","year":"1976","unstructured":"Gonzalez-Vitale J, Garcia-Bunuel R: Meningeal carcinomatosis. Cancer 1976, 37:2906\u20132911.","journal-title":"Cancer"},{"key":"84_CR23","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1023\/A:1005956925637","volume":"38","author":"LM DeAngelis","year":"1998","unstructured":"DeAngelis LM: Current diagnosis and treatment of leptomeningeal metastasis. J Neuro Oncol 1998, 38:245\u2013252.","journal-title":"J Neuro Oncol"},{"key":"84_CR24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/1097-0142(19930701)72:1<261::AID-CNCR2820720146>3.0.CO;2-O","volume":"72","author":"R Gelber","year":"1993","unstructured":"Gelber R, Sallan S, Cohen H, et al.: Central nervous system treatment in childhood acute lymphoblastic leukemia. Cancer 1993, 72:261\u2013270.","journal-title":"Cancer"},{"key":"84_CR25","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1200\/JCO.1995.13.2.333","volume":"13","author":"R Ribeiro","year":"1995","unstructured":"Ribeiro R, Rivera G, Hudson M, et al.: An intensive re-treatment protocol for children with an isolated CNS relapse of acute lymphoblastic leukemia. J Clin Oncol 1995, 13:333\u2013358.","journal-title":"J Clin Oncol"},{"key":"84_CR26","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.1995.13.2.310","volume":"13","author":"P Steinherz","year":"1995","unstructured":"Steinherz P: CNS leukemia: problem of diagnosis, outcome, and treatment. J Clin Oncol 1995, 13:310\u2013313.","journal-title":"J Clin Oncol"},{"key":"84_CR27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/00023210-199810010-00003","volume":"10","author":"M Chamberlain","year":"1998","unstructured":"Chamberlain M, Kormanik PA: Neoplastic meningitis: a guide to diagnosis and treatment. CNS Drugs 1998, 10:25\u201341.","journal-title":"CNS Drugs"},{"key":"84_CR28","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1212\/WNL.29.10.1369","volume":"29","author":"J Glass","year":"1979","unstructured":"Glass J, Melamed M, Chernik N, et al.: Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 1979, 29:1369\u20131375.","journal-title":"Neurology"},{"key":"84_CR29","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1212\/WNL.40.3_Part_1.435","volume":"40","author":"M Chamberlain","year":"1990","unstructured":"Chamberlain M, Sandy A, Press G: Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrastenhanced CT of the brain. Neurology 1990, 40:435\u2013438.","journal-title":"Neurology"},{"key":"84_CR30","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/BF01059954","volume":"23","author":"MC Chamberlain","year":"1995","unstructured":"Chamberlain MC: Comparative spine imaging in leptomeningeal metastases. J Neurooncol 1995, 23:233\u2013238.","journal-title":"J Neurooncol"},{"key":"84_CR31","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0733-8619(18)30252-4","volume":"9","author":"S Grossman","year":"1991","unstructured":"Grossman S, Moynihan T: Neurologic complications of systemic cancer: neoplastic meningitis. Neurol Clin 1991, 9:843\u2013856.","journal-title":"Neurol Clin"},{"key":"84_CR32","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1985.3.4.485","volume":"3","author":"F Balis","year":"1985","unstructured":"Balis F, Savitch J, Bleyer W, et al.: Remission induction of meningeal leukemia with high-dose intravenous methotrexate. J Clin Oncol 1985, 3:485\u2013489.","journal-title":"J Clin Oncol"},{"key":"84_CR33","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM197507242930402","volume":"293","author":"W Shapiro","year":"1975","unstructured":"Shapiro W, Young D, Mehta B: Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular, and lumbar injections. N Engl J Med 1975, 293:161\u2013166.","journal-title":"N Engl J Med"},{"key":"84_CR34","first-page":"237","volume-title":"Principles and Practice of Pediatric Oncology","author":"F Balis","year":"2002","unstructured":"Balis F, Holcenberg J, Blaney S: General principles of chemotherapy. In Principles and Practice of Pediatric Oncology. Edited by Pizzo P, Poplack D. Philadelphia: Lippincott, Williams & Wilkins; 2002:237\u2013308."},{"key":"84_CR35","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1200\/JCO.1984.2.5.365","volume":"2","author":"J Frick","year":"1984","unstructured":"Frick J, Ritch PS, Hansen RN, Anderson T: Successful treatment of meningeal leukemia using systemic high-dose cytosine arabinoside. J Clin Oncol 1984, 2:365\u2013368.","journal-title":"J Clin Oncol"},{"key":"84_CR36","first-page":"1059","volume":"70","author":"RC Donehower","year":"1986","unstructured":"Donehower RC, Karp JE, Burke PJ: Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. Cancer Treat Rep 1986, 70:1059\u20131065.","journal-title":"Cancer Treat Rep"},{"key":"84_CR37","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.1986.4.4.571","volume":"4","author":"S Nand","year":"1986","unstructured":"Nand S, Messmore H, Patel R, et al.: Neurotoxicity associated with systemic high-dose cytosine arabinoside. J Clin Oncol 1986, 4:571\u2013575.","journal-title":"J Clin Oncol"},{"key":"84_CR38","first-page":"736","volume":"49","author":"R Heideman","year":"1989","unstructured":"Heideman R, Cole D, Balis F, et al.: Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 1989, 49:736\u2013741.","journal-title":"Cancer Res"},{"key":"84_CR39","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/1097-0142(19930701)72:1<271::AID-CNCR2820720147>3.0.CO;2-K","volume":"72","author":"RL Heideman","year":"1992","unstructured":"Heideman RL, Packer RJ, Reaman GH, et al.: A phase II evaluation of thiotepa in central nervous system malignancies. Cancer 1992, 72:271\u2013275.","journal-title":"Cancer"},{"key":"84_CR40","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.1983.1.9.546","volume":"1","author":"M Slevin","year":"1983","unstructured":"Slevin M, Piall E, Aherne G, et al.: Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol 1983, 1:546\u2013551.","journal-title":"J Clin Oncol"},{"key":"84_CR41","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF02228887","volume":"3","author":"J Lopez","year":"1985","unstructured":"Lopez J, Nassif E, Vannicola P, et al.: Central nervous system pharmacokinetics of high-dose cytosine arabinoside. J Neurooncol 1985, 3:119\u2013124.","journal-title":"J Neurooncol"},{"key":"84_CR42","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.1987.5.12.2017","volume":"5","author":"S Ackland","year":"1987","unstructured":"Ackland S, Schilsky R: High-dose methotrexate: a critical reappraisal. J Clin Oncol 1987, 5:2017\u20132031.","journal-title":"J Clin Oncol"},{"key":"84_CR43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00043426-198921000-00017","volume":"11","author":"F Balis","year":"1989","unstructured":"Balis F, Poplack D: Central nervous system pharmacology of antileukemic drugs. Am J Pediatr Hematol Oncol 1989, 11:74\u201386.","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"84_CR44","first-page":"521","volume":"5","author":"MC Chamberlain","year":"1998","unstructured":"Chamberlain MC, Kormanik P, Glantz M: Recurrent primary central nervous system lymphoma complicated by lymphomatous meningitis. Oncol Rep 1998, 5:521\u2013523.","journal-title":"Oncol Rep"},{"key":"84_CR45","first-page":"4418","volume":"36","author":"H Pinedo","year":"1976","unstructured":"Pinedo H, Zaharko D, Bull J, et al.: The reversal of methotrexate cytotoxicity to mouse bone marrow cells by Leucovorin and nucleosides. Cancer Res 1976, 36:4418\u20134424.","journal-title":"Cancer Res"},{"key":"84_CR46","unstructured":"Widemann B, Hetherington M, Smithson W, et al.: Carboxypeptidase-G2 as a rescue agent following methotrexate induced renal failure or intrathecal methotrexate overdose [abstract]. Proc Am Assoc Cancer Res 1995:1384."},{"key":"84_CR47","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1200\/JCO.1986.4.12.1845","volume":"4","author":"R Walker","year":"1986","unstructured":"Walker R, Allen J, Rosen G, Caparros B: Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol 1986, 4:1845\u20131950.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"84_CR48","first-page":"89","volume":"65","author":"W Bleyer","year":"1981","unstructured":"Bleyer W: Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat Rep 1981, 65(Suppl 1):89\u201398.","journal-title":"Cancer Treat Rep"},{"key":"84_CR49","first-page":"6101","volume":"46","author":"J Strong","year":"1986","unstructured":"Strong J, Collins J, Lester C, Poplack D: Pharmacokinetics of intraventricular and intravenous N,N\u2019,N\u2019-triethylenethiophosphoramide (thiotepa) in rhesus monkeys and humans. Cancer Res 1986, 46:6101\u20136104.","journal-title":"Cancer Res"},{"key":"84_CR50","first-page":"1869","volume":"45","author":"S Zimm","year":"1985","unstructured":"Zimm S, Ettinger L, Holcenberg J, et al.: Phase I and clinical pharmacological study of 6-mercaptopurine administered as a prolonged intravenous infusion. Cancer Res 1985, 45:1869\u20131873.","journal-title":"Cancer Res"},{"key":"84_CR51","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF02897290","volume":"26","author":"P Adamson","year":"1990","unstructured":"Adamson P, Zimm S, Ragab A, et al.: A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors. Cancer Chemother Pharmacol 1990, 26:343\u2013344.","journal-title":"Cancer Chemother Pharmacol"},{"key":"84_CR52","first-page":"725","volume":"53","author":"S Blaney","year":"1993","unstructured":"Blaney S, Cole D, Balis F, et al.: Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 1993, 53:725\u2013727.","journal-title":"Cancer Res"},{"key":"84_CR53","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/(SICI)1097-0142(19960801)78:3<527::AID-CNCR21>3.0.CO;2-#","volume":"78","author":"SM Blaney","year":"1996","unstructured":"Blaney SM, Phillips PC, Packer RJ, et al.: Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer 1996, 78:527\u2013531.","journal-title":"Cancer"},{"key":"84_CR54","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1160::AID-CNCR21>3.0.CO;2-F","volume":"85","author":"HS Friedman","year":"1999","unstructured":"Friedman HS, Kerby T, Fields S, et al.: Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke. Cancer 1999, 85:1160\u20131165.","journal-title":"Cancer"},{"key":"84_CR55","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/oxfordjournals.annonc.a010550","volume":"7","author":"D Macdonald","year":"1996","unstructured":"Macdonald D, Cairncross G, Stewart D, et al.: Phase II study of Topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group. Ann Oncol 1996, 7:205\u2013207.","journal-title":"Ann Oncol"},{"key":"84_CR56","first-page":"256","volume":"24","author":"C Oberhoff","year":"2001","unstructured":"Oberhoff C, Kieback DG, Wurstlein R, et al.: Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. Onkologie 2001, 24:256\u2013260.","journal-title":"Onkologie"},{"key":"84_CR57","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s002800050768","volume":"41","author":"SM Blaney","year":"1998","unstructured":"Blaney SM, Takimoto C, Murry DJ, et al.: Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. Cancer Chemother Pharmacol 1998, 41:464\u2013468.","journal-title":"Cancer Chemother Pharmacol"},{"key":"84_CR58","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1200\/JCO.1999.17.5.1516","volume":"17","author":"HS Friedman","year":"1999","unstructured":"Friedman HS, Petros WP, Friedman AH, et al.: Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999, 17:1516\u20131525.","journal-title":"J Clin Oncol"},{"key":"84_CR59","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1014532202188","volume":"56","author":"MC Chamberlain","year":"2002","unstructured":"Chamberlain MC: Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neuroncol 2002, 56:183\u2013188.","journal-title":"J Neuroncol"},{"key":"84_CR60","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1023\/A:1019608404378","volume":"59","author":"MC Chamberlain","year":"2002","unstructured":"Chamberlain MC: Salvage chemotherapy with CPT-11 for oligodendroglioma. J Neurooncol 2002, 59:157\u2013163.","journal-title":"J Neurooncol"},{"key":"84_CR61","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.1987.5.2.202","volume":"5","author":"F Balis","year":"1987","unstructured":"Balis F, Lester C, Chrousos G, et al.: Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol 1987, 5:202\u2013207.","journal-title":"J Clin Oncol"},{"key":"84_CR62","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/mpo.2950190411","volume":"19","author":"B Jones","year":"1991","unstructured":"Jones B, Freeman AI, Shuster JJ, et al.: Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 1991, 19:269\u2013275.","journal-title":"Med Pediatr Oncol"},{"key":"84_CR63","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/(SICI)1097-0142(20000415)88:8<1964::AID-CNCR27>3.0.CO;2-1","volume":"88","author":"CA Hurwitz","year":"2000","unstructured":"Hurwitz CA, Silverman LB, Schorin MA, et al.: Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer 2000, 88:1964\u20131969.","journal-title":"Cancer"},{"key":"84_CR64","first-page":"3394","volume":"5","author":"MJ Glantz","year":"1999","unstructured":"Glantz MJ, Jaeckle KA, Chamberlain MC, et al.: A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999, 5:3394\u20133402. One of two recent randomized clinical trials comparing sustainedrelease Ara-C with methotrexate in adults with neloplastic meningitis secondary to solid cancer.","journal-title":"Clin Cancer Res"},{"key":"84_CR65","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.1999.17.10.3110","volume":"17","author":"M Glantz","year":"1999","unstructured":"Glantz M, Chamberlain MC, Shapiro W, et al.: A randomized trial of a slow-release formulation of cytarabine for the treatment of lymphomatous meningitis. J Clin Oncol 1999, 17:3110\u20133116. One of two recent randomized clinical trials comparing sustained release Ara-C with standard Ara-C and the only randomized trial in patients with lymphomatous meningitis.","journal-title":"J Clin Oncol"},{"key":"84_CR66","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/1097-0142(197002)25:2<306::AID-CNCR2820250206>3.0.CO;2-H","volume":"25","author":"L Tallal","year":"1970","unstructured":"Tallal L, Tan C, Oettgen H, et al.: E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer 1970, 25:306\u2013320.","journal-title":"Cancer"},{"key":"84_CR67","doi-asserted-by":"crossref","first-page":"893","DOI":"10.7326\/0003-4819-74-6-893","volume":"74","author":"R Capizzi","year":"1971","unstructured":"Capizzi R, Bertino J, Skeel R, et al.: L-Asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med 1971, 74:893\u2013901.","journal-title":"Ann Intern Med"},{"key":"84_CR68","first-page":"349","volume":"14","author":"D Ho","year":"1986","unstructured":"Ho D, Brown N, Yen A, et al.: Clinical pharmacology of polyethylene glycol L-asparaginase. Drug Metab Dispos 1986, 14:349\u2013352.","journal-title":"Drug Metab Dispos"},{"key":"84_CR69","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/BF00686177","volume":"32","author":"S Berg","year":"1993","unstructured":"Berg S, Balis F, McCully C, et al.: Pharmacokinetics of PEG-L-asparaginase and plasma and cerebrospinal fluid L-asparagine concentrations in the Rhesus monkey. Cancer Chemother Pharmacol 1993, 32:310\u2013314.","journal-title":"Cancer Chemother Pharmacol"},{"key":"84_CR70","first-page":"4554","volume":"41","author":"R Riccardi","year":"1981","unstructured":"Riccardi R, Holcenberg J, Glaubiger D, et al.: L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 1981, 41:4554\u20134558.","journal-title":"Cancer Res"},{"key":"84_CR71","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF00165710","volume":"1","author":"J Collins","year":"1983","unstructured":"Collins J: Pharmacokinetics of intraventricular administration. J Neurooncol 1983, 1:283\u2013291.","journal-title":"J Neurooncol"},{"key":"84_CR72","first-page":"633","volume":"61","author":"R Blasberg","year":"1977","unstructured":"Blasberg R, Patlak C, Shapiro W: Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration. Cancer Treat Rep 1977, 61:633\u2013641.","journal-title":"Cancer Treat Rep"},{"key":"84_CR73","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1212\/WNL.41.11.1765","volume":"41","author":"MC Chamberlain","year":"1991","unstructured":"Chamberlain MC, Corey-Bloom J: Leptomeningeal metastases: 111indium-DTPA CSF flow studies. Neurology 1991, 41:1765\u20131769.","journal-title":"Neurology"},{"key":"84_CR74","first-page":"555","volume":"12","author":"S Larson","year":"1971","unstructured":"Larson S, Schall G, DiChiro G: The influence of previous lumbar puncture and pneumoencephalography on the incidence of unsuccessful radioisotope cisternography. J Nuclear Med 1971, 12:555\u2013557.","journal-title":"J Nuclear Med"},{"key":"84_CR75","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1200\/JCO.1987.5.10.1655","volume":"5","author":"R Hitchens","year":"1987","unstructured":"Hitchens R, Bell D, Woods R, et al.: A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987, 5:1655\u20131662.","journal-title":"J Clin Oncol"},{"key":"84_CR76","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1200\/JCO.1986.4.1.68","volume":"4","author":"L Giannone","year":"1986","unstructured":"Giannone L, Greco F, Hainsworth J: Combination intraventricular chemotherapy for meningeal neoplasia. J Clin Oncol 1986, 4:68\u201373.","journal-title":"J Clin Oncol"},{"key":"84_CR77","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1200\/JCO.1993.11.3.561","volume":"11","author":"SA Grossman","year":"1993","unstructured":"Grossman SA, Finkelstein DM, Ruckdeschel JC, et al.: Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 1993, 11:561\u2013569.","journal-title":"J Clin Oncol"},{"key":"84_CR78","first-page":"274","volume":"11","author":"S Blaney","year":"1992","unstructured":"Blaney S, Balis F, Murphy R, et al.: A phase I study of intrathecal mafosfamide in patients with refractory meningeal malignancy [abstract]. Proc ASCO 1992, 11:274.","journal-title":"Proc ASCO"},{"key":"84_CR79","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1023\/A:1005940405165","volume":"38","author":"I Slavc","year":"1998","unstructured":"Slavc I, Schuller E, Czech T, et al.: Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination. J Neurooncol 1998, 38:213\u2013218.","journal-title":"J Neurooncol"},{"key":"84_CR80","unstructured":"Blaney S, Horowitz M, Kun L, et al.: A new approach to the treatment of infants with CNS tumors. Presentation at the Society for Neuro-Oncology. San Francisco, CA, June 11, 2000."},{"key":"84_CR81","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF01052668","volume":"24","author":"DD Bigner","year":"1995","unstructured":"Bigner DD, Brown M, Coleman RE, et al.: Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab\u2019) 2: a preliminary report. J Neurooncol 1995, 24:109\u2013122.","journal-title":"J Neurooncol"},{"key":"84_CR82","first-page":"963","volume":"2","author":"MT Brown","year":"1996","unstructured":"Brown MT, Coleman RE, Friedman AH, et al.: Intrathecal 131Ilabeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clin Cancer Res 1996, 2:963\u2013972.","journal-title":"Clin Cancer Res"},{"key":"84_CR83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/jns.1992.76.1.0001","volume":"76","author":"WA Hall","year":"1992","unstructured":"Hall WA, Fodstad O: Immunotoxins and central nervous system neoplasia. J Neurosurg 1992, 76:1\u201312.","journal-title":"J Neurosurg"},{"key":"84_CR84","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-3-642-79952-5_10","volume":"141","author":"JT Kemshead","year":"1996","unstructured":"Kemshead JT, Hopkins KI, Chandler CL: Treatment of diffuse leptomeningeal malignancy by intrathecal injection of 131I radioimmunoconjugates. Recent Results Cancer Res 1996, 141:145\u2013158.","journal-title":"Recent Results Cancer Res"},{"key":"84_CR85","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1038\/bjc.1998.386","volume":"77","author":"JT Kemshead","year":"1998","unstructured":"Kemshead JT, Hopkins K, Pizer B, et al.: Dose escalation with repeated intrathecal injections of 131I-labelled MAbs for the treatment of central nervous system malignancies. Br J Cancer 1998, 77:2324\u20132330.","journal-title":"Br J Cancer"},{"key":"84_CR86","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/ijc.2910520109","volume":"52","author":"RP Moseley","year":"1992","unstructured":"Moseley RP, Papanastassiou V, Zalutsky MR, et al.: Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates. Int J Cancer 1992, 52:38\u201343.","journal-title":"Int J Cancer"},{"key":"84_CR87","doi-asserted-by":"crossref","unstructured":"Youle RJ: Immunotoxins for central nervous system malignancy. Semin Cancer Biol 1996, 65\u201370.","DOI":"10.1006\/scbi.1996.0010"},{"key":"84_CR88","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/cncr.10547","volume":"94","author":"MC Chamberlain","year":"2002","unstructured":"Chamberlain MC: A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer 2002, 94:2675\u20132680.","journal-title":"Cancer"},{"key":"84_CR89","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1200\/JCO.1992.10.1.143","volume":"10","author":"S Berg","year":"1992","unstructured":"Berg S, Balis F, Zimm S, et al.: Phase I\/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies. J Clin Oncol 1992, 10:143\u2013148.","journal-title":"J Clin Oncol"},{"key":"84_CR90","first-page":"5932","volume":"47","author":"C Arndt","year":"1987","unstructured":"Arndt C, Colvin O, Balis F, et al.: Intrathecal administration of 4-hydroperoxycyclophosphamide in rhesus monkeys. Cancer Res 1987, 47:5932\u20135934.","journal-title":"Cancer Res"},{"key":"84_CR91","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.V51.5.835.835","volume":"51","author":"W Bleyer","year":"1978","unstructured":"Bleyer W, Poplack D, Simon R: \u2019Concentration x time\u2019 methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood 1978, 51:835\u2013842.","journal-title":"Blood"},{"key":"84_CR92","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1200\/JCO.1993.11.10.1978","volume":"11","author":"M Chamberlain","year":"1993","unstructured":"Chamberlain M, Dirr L: Involved field radiotherapy and intraommaya methotrexate\/ara-C in patients with AIDS-related lymphomatous meningitis. J Clin Oncol 1993, 11:1978\u20131984.","journal-title":"J Clin Oncol"},{"key":"84_CR93","first-page":"505","volume":"9","author":"MC Chamberlain","year":"1996","unstructured":"Chamberlain MC, Kormanik P: Leptomeningeal metastases due to melanoma: combined modality therapy. Int J Oncol 1996, 9:505\u2013510.","journal-title":"Int J Oncol"},{"key":"84_CR94","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1023\/A:1005803918194","volume":"35","author":"MC Chamberlain","year":"1997","unstructured":"Chamberlain MC, Kormanik PA: Carcinomatous meningitis secondary to breast cancer: combined modality therapy. J Neurooncol 1997, 35:55\u201364.","journal-title":"J Neurooncol"},{"key":"84_CR95","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1001\/archneur.55.4.506","volume":"55","author":"MC Chamberlain","year":"1998","unstructured":"Chamberlain MC, Kormanik PA: Carcinomatous meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol 1998, 55:506\u2013512.","journal-title":"Arch Neurol"},{"key":"84_CR96","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1212\/WNL.49.6.1728","volume":"49","author":"MC Chamberlain","year":"1997","unstructured":"Chamberlain MC, Kormanik PA: Non-AIDS related lymphomatous meningitis: combined modality therapy. Neurology 1997, 49:1728\u20131731.","journal-title":"Neurology"},{"key":"84_CR97","first-page":"521","volume":"5","author":"MC Chamberlain","year":"1998","unstructured":"Chamberlain MC, Kormanik PA: Lymphomatous meningitis in immunocompromised patients: combined modality therapy. Oncol Rep 1998, 5:521\u2013525.","journal-title":"Oncol Rep"},{"key":"84_CR98","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1054\/bjoc.2000.1574","volume":"84","author":"KA Jaeckle","year":"2001","unstructured":"Jaeckle KA, Phuphanich S, Bent MJ, et al.: Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 2001, 84:157\u2013163. An excellent review of the treatment of women with breast cancer and neoplastic meningitis.","journal-title":"Br J Cancer"},{"key":"84_CR99","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3171\/jns.1997.87.5.0694","volume":"87","author":"MC Chamberlain","year":"1997","unstructured":"Chamberlain MC, Kormanik PA: Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 1997, 87:694\u2013699.","journal-title":"J Neurosurg"},{"key":"84_CR100","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/archinte.1990.00390130145023","volume":"150","author":"M Lishner","year":"1990","unstructured":"Lishner M, Perrin R, Feld R, et al.: Complications associated with ommaya reservoirs in patients with cancer. Arch Intern Med 1990, 150:173\u2013176.","journal-title":"Arch Intern Med"},{"key":"84_CR101","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00043426-198921000-00019","volume":"11","author":"J Ochs","year":"1989","unstructured":"Ochs J: Neurotoxicity due to central nervous system therapy for childhood leukemia. Am J Pediatr Hematol Oncol 1989, 11:93\u2013105.","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"84_CR102","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1056\/NEJM197310112891503","volume":"289","author":"W Bleyer","year":"1973","unstructured":"Bleyer W, Drake J, Chabner B: Neurotoxicity and elevated cerebrospinal fluid methotrexate concentration in meningeal leukemia. N Engl J Med 1973, 289:770\u2013773.","journal-title":"N Engl J Med"},{"key":"84_CR103","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/978-94-009-6708-3_9","volume-title":"Central Nervous System Leukemia","author":"R Price","year":"1983","unstructured":"Price R: Therapy related central nervous system diseases in children with acute lymphocytic leukemia. In Central Nervous System Leukemia. Edited by Mastrangelo R, Poplack D, Riccardi R. Boston: Martinus Nijhoff Publishers; 1983:71\u201381."},{"key":"84_CR104","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0022-3476(81)80859-1","volume":"98","author":"J Addegio","year":"1981","unstructured":"Addegio J, Ridgway D, Bleyer W: The acute management of intrathecal methotrexate overdose: pharmacologic rationale and guidelines. J Pediatr 1981, 98:825\u2013828.","journal-title":"J Pediatr"},{"key":"84_CR105","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0889-8588(18)30463-5","volume":"4","author":"C Pochedly","year":"1990","unstructured":"Pochedly C: Prevention of meningeal leukemia: review of 20 years of research and current recommendations. Hematol Oncol Clin North Am 1990, 4:951\u2013969.","journal-title":"Hematol Oncol Clin North Am"},{"key":"84_CR106","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1200\/JCO.1991.9.4.670","volume":"9","author":"PC Adamson","year":"1991","unstructured":"Adamson PC, Balis FM, McCully CL, et al.: Rescue of experimental intrathecal methotrexate overdose with carboxypeptidase-G2. J Clin Oncol 1991, 9:670\u2013674.","journal-title":"J Clin Oncol"},{"key":"84_CR107","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/mpo.2950060304","volume":"6","author":"W Bleyer","year":"1979","unstructured":"Bleyer W, Poplack D: Intraventricular versus intralumbar methotrexate for central nervous-system leukemia: prolonged remission with the Ommaya reservoir. Med Pediatr Oncol 1979, 6:207\u2013213.","journal-title":"Med Pediatr Oncol"},{"key":"84_CR108","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.1983.1.5.317","volume":"1","author":"W Bleyer","year":"1983","unstructured":"Bleyer W, Coccia P, Sather H, et al.: Reduction in the incidence of central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. J Clin Oncol 1983, 1:317\u2013325.","journal-title":"J Clin Oncol"},{"key":"84_CR109","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/1097-0142(197202)29:2<370::AID-CNCR2820290217>3.0.CO;2-Z","volume":"29","author":"J Saiki","year":"1972","unstructured":"Saiki J, Thompson S, Smith F, Atkinson R: Paraplegia following intrathecal chemotherapy. Cancer 1972, 29:370\u2013374.","journal-title":"Cancer"},{"key":"84_CR110","first-page":"3349","volume":"5","author":"WA Bleyer","year":"1999","unstructured":"Bleyer WA: Intrathecal depot cytarabine therapy: a welcome addition to the therapeutic armamentarium. Clin Cancer Res 1999, 5:3349\u20133351.","journal-title":"Clin Cancer Res"},{"key":"84_CR111","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/1097-0142(19910315)67:6<1685::AID-CNCR2820670635>3.0.CO;2-M","volume":"67","author":"W Boogerd","year":"1991","unstructured":"Boogerd W, Hart AAM, Van der Sande JJ, et al.: Meningeal carcinomatosis in breast cancer: prognostic factors and influence of treatment. Cancer 1991, 67:1685\u20131695.","journal-title":"Cancer"},{"key":"84_CR112","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1315::AID-CNCR14>3.0.CO;2-4","volume":"77","author":"K Fizazi","year":"1996","unstructured":"Fizazi K, Asselain B, Vincent-Salomon A, et al.: Meningeal carcinomatosis in patients with breast carcinoma. Cancer 1996, 77:1315\u20131323.","journal-title":"Cancer"},{"key":"84_CR113","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1002\/1097-0142(19950615)75:12<2919::AID-CNCR2820751220>3.0.CO;2-9","volume":"75","author":"M Glantz","year":"1995","unstructured":"Glantz M, Hall WA, Cole BF, et al.: Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow studies. Cancer 1995, 75:2919\u20132931.","journal-title":"Cancer"},{"key":"84_CR114","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1001\/archneur.1996.00550070064013","volume":"53","author":"M Balm","year":"1996","unstructured":"Balm M, Hammack J: Leptomeningeal carcinomatosis. Arch Neurol 1996, 53:626\u2013632.","journal-title":"Arch Neurol"},{"key":"84_CR115","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1212\/WNL.44.8.1463","volume":"44","author":"T Siegal","year":"1994","unstructured":"Siegal T, Lossos A, Pfeffer MR: Leptomeningeal metastasis: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 1994, 44:1463\u20131469.","journal-title":"Neurology"},{"key":"84_CR116","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1212\/WNL.46.6.1674","volume":"46","author":"MC Chamberlain","year":"1996","unstructured":"Chamberlain MC, Kormanik P: Prognostic significance of 111Indium-DTPA CSF flow studies. Neurology 1996, 46:1674\u20131677.","journal-title":"Neurology"},{"key":"84_CR117","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1001\/archneur.1997.00550230037013","volume":"54","author":"MC Chamberlain","year":"1997","unstructured":"Chamberlain MC, Kormanik PA: Prognostic significance of co-existent bulky metastatic CNS disease in patients with leptomeningeal metastases. Arch Neurol 1997, 54:1364\u20131368.","journal-title":"Arch Neurol"},{"key":"84_CR118","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0002-9343(82)90404-1","volume":"73","author":"S Grossman","year":"1982","unstructured":"Grossman S, Trump D, Chen D, et al.: Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. Am J Med 1982, 73:641\u2013647.","journal-title":"Am J Med"},{"key":"84_CR119","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3171\/foc.1998.4.6.7","volume":"4","author":"M Glantz","year":"1998","unstructured":"Glantz M, Chamberlain MC, Walters BC: Diagnosis and outcome measures for neoplastic meningitis: a review of the literature and clinical experience. Neurosurg Focus 1998, 4:8\u201316.","journal-title":"Neurosurg Focus"},{"key":"84_CR120","first-page":"795","volume":"59","author":"R Dedrick","year":"1975","unstructured":"Dedrick R, Zaharko D, Bender R, et al.: Pharmacokinetic considerations on resistance to anticancer drugs. Cancer Chemother Rep 1975, 59:795\u2013804.","journal-title":"Cancer Chemother Rep"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-003-0084-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-003-0084-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-003-0084-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T16:49:25Z","timestamp":1587574165000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-003-0084-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2]]},"references-count":120,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,2]]}},"alternative-id":["84"],"URL":"https:\/\/doi.org\/10.1007\/s11912-003-0084-9","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,2]]}}}